158 related articles for article (PubMed ID: 19142638)
1. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.
Kim HJ; Lee NS; Lee SC; Bae SB; Kim CK; Cheon YG; Kim YS; Moon JH; Cho YD; Park SH; Lee KT; Park SK; Won JH; Park HS; Hong DS
Cancer Chemother Pharmacol; 2009 Jul; 64(2):371-7. PubMed ID: 19142638
[TBL] [Abstract][Full Text] [Related]
2. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
Manzione L; Romano R; Germano D
Oncology; 2007; 73(5-6):311-5. PubMed ID: 18493158
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
[No Abstract] [Full Text] [Related]
5. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
6. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Kornek GV; Schuell B; Laengle F; Gruenberger T; Penz M; Karall K; Depisch D; Lang F; Scheithauer W
Ann Oncol; 2004 Mar; 15(3):478-83. PubMed ID: 14998852
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
Graham JS; Boyd K; Coxon FY; Wall LR; Eatock MM; Maughan TS; Highley M; Soulis E; Harden S; Bützberger-Zimmerli P; Evans TR
BMC Res Notes; 2016 Mar; 9():161. PubMed ID: 26969121
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
El-Hadaad HA; Wahba HA
J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
Lee J; Kim TY; Lee MA; Ahn MJ; Kim HK; Lim HY; Lee NS; Park BJ; Kim JS;
Cancer Chemother Pharmacol; 2008 Jan; 61(1):47-52. PubMed ID: 17364190
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
Lee KH; Kim MK; Kim YH; Ryoo BY; Lim HY; Song HS; Kim HK; Lee MA; Im SA; Chang HM; Cho JY; Zang DY; Kim BS; Kim JS
Cancer Chemother Pharmacol; 2009 Jul; 64(2):317-25. PubMed ID: 19034448
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas.
Halim A; Ebrahim MA; Saleh Y
Jpn J Clin Oncol; 2011 Feb; 41(2):217-24. PubMed ID: 21062755
[TBL] [Abstract][Full Text] [Related]
15. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS
Oncology; 2009; 76(5):333-7. PubMed ID: 19307739
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
Jang JS; Lim HY; Hwang IG; Song HS; Yoo N; Yoon S; Kim YH; Park E; Byun JH; Lee MA; Oh SJ; Lee KH; Kim BS; Oh SC; Kim SY; Lee SJ
Cancer Chemother Pharmacol; 2010 Mar; 65(4):641-7. PubMed ID: 19652971
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
20. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer.
Harder J; Riecken B; Kummer O; Lohrmann C; Otto F; Usadel H; Geissler M; Opitz O; Henss H
Br J Cancer; 2006 Oct; 95(7):848-52. PubMed ID: 16969352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
